For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Upstream Bio Inc (NASDAQ: UPB) closed at $17.13 in the last session, up 2.21% from day before closing price of $16.76. In other words, the price has increased by $2.21 from its previous closing price. On the day, 0.31 million shares were traded. UPB stock price reached its highest trading level at $17.22 during the session, while it also had its lowest trading level at $16.37.
Ratios:
We take a closer look at UPB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 38.27 and its Current Ratio is at 38.27. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 05, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $75.Piper Sandler initiated its Overweight rating on November 05, 2024, with a $75 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 15 ’24 when Chimovits Erez bought 825,000 shares for $17.00 per share. The transaction valued at 14,025,000 led to the insider holds 4,554,873 shares of the business.
ORBIMED ADVISORS LLC bought 825,000 shares of UPB for $14,025,000 on Oct 15 ’24. The Director now owns 4,554,873 shares after completing the transaction at $17.00 per share. On Oct 15 ’24, another insider, AI Upstream LLC, who serves as the 10% Owner of the company, bought 1,175,000 shares for $17.00 each. As a result, the insider paid 19,975,000 and bolstered with 1,175,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, UPB now has a Market Capitalization of 923467968 and an Enterprise Value of 531448480. For the stock, the TTM Price-to-Sale (P/S) ratio is 339.51 while its Price-to-Book (P/B) ratio in mrq is 2.25. Its current Enterprise Value per Revenue stands at 195.17 whereas that against EBITDA is -4.377.
Stock Price History:
Over the past 52 weeks, UPB has reached a high of $29.46, while it has fallen to a 52-week low of $5.14. The 50-Day Moving Average of the stock is 22.76%, while the 200-Day Moving Average is calculated to be 37.41%.
Shares Statistics:
According to the various share statistics, UPB traded on average about 463.92K shares per day over the past 3-months and 356880 shares per day over the past 10 days. A total of 53.80M shares are outstanding, with a floating share count of 20.09M. Insiders hold about 63.10% of the company’s shares, while institutions hold 52.99% stake in the company. Shares short for UPB as of 1755216000 were 3160080 with a Short Ratio of 6.81, compared to 1752537600 on 3781146. Therefore, it implies a Short% of Shares Outstanding of 3160080 and a Short% of Float of 10.5900005.
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of Upstream Bio Inc (UPB) in the stock market.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.69 and low estimates of -$0.81.
Analysts are recommending an EPS of between -$2.6 and -$2.88 for the fiscal current year, implying an average EPS of -$2.79. EPS for the following year is -$2.98, with 4.0 analysts recommending between -$2.67 and -$3.45.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for UPB’s current fiscal year. The highest revenue estimate was $3.52M, while the lowest revenue estimate was $1.5M, resulting in an average revenue estimate of $2.77M. In the same quarter a year ago, actual revenue was $2.37M
